Cargando…

Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes

The aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were t...

Descripción completa

Detalles Bibliográficos
Autores principales: Voizard, Nicolas, Ni, Tiffany, Kiss, Alex, Pugash, Robyn, Raphael, Michael Jonathon, Coburn, Natalie, David, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774320/
https://www.ncbi.nlm.nih.gov/pubmed/35049694
http://dx.doi.org/10.3390/curroncol29010020
_version_ 1784636312908726272
author Voizard, Nicolas
Ni, Tiffany
Kiss, Alex
Pugash, Robyn
Raphael, Michael Jonathon
Coburn, Natalie
David, Elizabeth
author_facet Voizard, Nicolas
Ni, Tiffany
Kiss, Alex
Pugash, Robyn
Raphael, Michael Jonathon
Coburn, Natalie
David, Elizabeth
author_sort Voizard, Nicolas
collection PubMed
description The aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were treated with DEBIRI-TACE between 2017 to 2020. Patients who received at least one session of DEBIRI were included in our analysis. A total of 105 DEBIRI sessions were completed. 86% of patients (n = 31) underwent one round of treatment, 14% of patients (n = 5) underwent two distinct rounds of treatment. The majority of patients were discharged the next day (92%, n = 33 patients) with no 30-day post-DEBIRI mortality. Five high-grade adverse events occurred, including longer stay for pain management (n = 2), postembolization syndrome requiring readmission (n = 2), and liver abscess (n = 1). The average survival from diagnosis of metastatic disease was 33.3 months (range 11–95, median 28). Nine of 36 patients are still alive (December 2020) and have an average follow-up time of 36.8 months from T0 (range 12–63, median 39). Small particle DEBIRI is safe and well-tolerated in the salvage setting, with outcomes comparable to that of larger bead sizes.
format Online
Article
Text
id pubmed-8774320
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87743202022-01-21 Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes Voizard, Nicolas Ni, Tiffany Kiss, Alex Pugash, Robyn Raphael, Michael Jonathon Coburn, Natalie David, Elizabeth Curr Oncol Article The aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were treated with DEBIRI-TACE between 2017 to 2020. Patients who received at least one session of DEBIRI were included in our analysis. A total of 105 DEBIRI sessions were completed. 86% of patients (n = 31) underwent one round of treatment, 14% of patients (n = 5) underwent two distinct rounds of treatment. The majority of patients were discharged the next day (92%, n = 33 patients) with no 30-day post-DEBIRI mortality. Five high-grade adverse events occurred, including longer stay for pain management (n = 2), postembolization syndrome requiring readmission (n = 2), and liver abscess (n = 1). The average survival from diagnosis of metastatic disease was 33.3 months (range 11–95, median 28). Nine of 36 patients are still alive (December 2020) and have an average follow-up time of 36.8 months from T0 (range 12–63, median 39). Small particle DEBIRI is safe and well-tolerated in the salvage setting, with outcomes comparable to that of larger bead sizes. MDPI 2022-01-06 /pmc/articles/PMC8774320/ /pubmed/35049694 http://dx.doi.org/10.3390/curroncol29010020 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Voizard, Nicolas
Ni, Tiffany
Kiss, Alex
Pugash, Robyn
Raphael, Michael Jonathon
Coburn, Natalie
David, Elizabeth
Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes
title Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes
title_full Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes
title_fullStr Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes
title_full_unstemmed Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes
title_short Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes
title_sort small particle debiri tace as salvage therapy in patients with liver dominant colorectal cancer metastasis: retrospective analysis of safety and outcomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774320/
https://www.ncbi.nlm.nih.gov/pubmed/35049694
http://dx.doi.org/10.3390/curroncol29010020
work_keys_str_mv AT voizardnicolas smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes
AT nitiffany smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes
AT kissalex smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes
AT pugashrobyn smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes
AT raphaelmichaeljonathon smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes
AT coburnnatalie smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes
AT davidelizabeth smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes